Stem cell-derived extracellular vesicles (SC-EVs) are promising cell-free therapeutics in regenerative medicine, enabling tissue repair, immune modulation, and treatment of aging-related diseases. By February 2026, their clinical use has extended to refractory conditions such as osteoarthritis, diabetic foot ulcers, and pulmonary fibrosis, with over 100 SC-EV trials registered on ClinicalTrials.gov — underscoring the urgency of clinical translation.
Precise characterization underpins the safety, efficacy, and standardized manufacturing of SC-EVs, yet progress is limited mainly by the lack of specific markers. Classical markers (CD9, CD63, CD81) are highly heterogeneous in SC-EVs and cannot reveal cellular origin. Defining SC-EV-specific marker profiles, building robust characterization technologies, and establishing a standardized “marker–function–quality” evaluation system are therefore central to clinical translation.


One Platform, Single-Particle, Multi-Parameter QC for Stem Cell EVs
